## HOW TO MANAGE DEPRESSIVE SYMPTOMS IN HIV

Practical recommendations

## CONTENTS

- 1. How common are depressive disorders?
- 2. What interventions are effective?
- 3. Practical management
- 4. Lessening the burden of chronic illness: the patients view

## HOW COMMON IS DEPRESSION IN PEOPLE WITH HIV INFECTION?

Published reports range from 0% to 80%

- Variation depends on many factors, such as instruments, population & stage of illness
- A significant minority experience significant depression

### HOW COMMON IS DEPRESSION?

*Psychology, Health & Medicine* 2011, 1–35, iFirst Article

Routledge

#### HIV and Depression – a systematic review of interventions

Lorraine Sherr<sup>a</sup>\*, Claudine Clucas<sup>a</sup>, Richard Harding<sup>b</sup>, Elissa Sibley<sup>a</sup> and Jose Catalan<sup>c</sup>

<sup>a</sup>Department of Infection and Population Health, University College London, London, UK; <sup>b</sup>Department of Palliative Care, Policy and Rehabilitation, Weston Education Centre, Kings College London, London, UK; <sup>c</sup>Central and North West London NHS Foundation Trust, London, UK

(Received 9 December 2010; final version received 6 April 2011)

HIV-positive individuals are more likely to be diagnosed with major depressive disorder than HIV-negative individuals. Depression can precede diagnosis and be associated with risk factors for infection. The experience of illness can also exacerbate depressive episodes and depression can be a side effect to treatment. A systematic understanding of which interventions have been tested in and are effective with HIV-seropositive individuals is needed. This review aims to provide a comprehensive understanding of evaluated interventions related to HIV and depression and provide some insight on questions of prevalence and measurement. Standard systematic research methods were used to gather quality published papers on HIV and depression. From the search, 1015 articles were generated and hand searched resulting in 90 studies meeting adequacy inclusion criteria for analysis. Of these, 67 (74.4%) were implemented in North America (the US and Canada) and 14 (15.5%) in Europe, with little representation from Africa, Asia and South America. Sixty-five (65.5%) studies recruited only men or mostly men, of which 31 (35%) recruited gay or bisexual men. Prevalence rates of

# HOW COMMON IS DEPRESSION?

### Examples of surveys

Psychology, Health & Medicine 9

Table 2.	Prevalence	of de	pression.
----------	------------	-------	-----------

Author and date of study	Sample size, n	Prevalence of depression	Measure and cut-off point
Avants et al. (1998)	6 in intervention and 8 in control	4 (66.7%) patients in intervention and 4 (50%) patients in control	BDI ≥ 17; range of moderate clinical depression.
Balfour et al. (2006)	63	42.8%	$CES-D \ge 16$ ; clinical levels of depressive symptoms
Gonzáles et al. (1993)	5 HIV positive	4 (80%)	DSM-III-R SCID major depression
Grinspoon et al. (2000)	59	21 (35.6%)	BDI > 18
Heckman and Carlson (2007)	299	71%	BDI ≥ 16; "moderate" or "severe" levels of depressive symptoms
Husbands et al. (2007)	79	40.5% very depressed and 59.5% less depressed	CES-D scores were divided at the mean $(\geq 28)$ into very and less depressed.
Mulder et al. (1994)	38?	88% in the low to mild range of the BDI. 12% within symptomatic ranges of depression.	BDI ≥ 16; symptomatic range of depression
Neidig et al. (2003)	60	35% according to CES-D, 20% according to BDI	CES-D $\geq$ 16; high level of depressive symptoms BDI $\geq$ 15, depression

## THE DANGERS OF DIAGNOSIS

#### ANALYSIS

C Feature: DSM-5: a fatal diagnosis? (BMJ 2013;346:f3256)

Head to Head: Are antidepressants overprescribed? No (BMJ 2013;346:f190)

Head to Head: Are antidepressants overprescribed? Yes (BMJ 2013;346:f191)

Research: Suicides associated with the 2008-10 economic recession in England (BMJ 2012;345:e5142)

• Research: Explaining the rise in antidepressant prescribing (BMJ 2009;339:b3999)

### Medicalising and medicating unhappiness

This article is part of a series on overdiagnosis looking at the risks and harms to patients of expanding definitions of disease and increasing use of new diagnostic technologies

any patients report sadness or distress during consultations with primary care doctors. Such emotions may be related to grief and other life stresses, including the stress of physical illness. Sometimes sadness appears out of the blue, without obvious relation to external causes. Over recent decades there has been an increasing tendency, especially in primary care, to diagnose depression (commonly major depressive disorder) in patients presenting with sadness or distress and offer them antidepressant medication.<sup>1-3</sup>

In this paper we offer a critical review of the diagnosis of major depressive disorder, show how and why this broad diagnostic label has resulted in overdiagnosis and overtreatment, and suggest how the approach to diagnosis and management of depression should change to reduce stigmatising the sad and provide better help for those who most need vigilant care and medical treatment.

#### **Evolving views of what constitutes depression** Descriptions of depression can be found in the Bible and Shakespeare, but no formal definition existed until the third version of the American Psychiatric Association's classification

can Psychiatric Association's classification systems for mental disorders was published in 1980 (DSM-III). The manual set out clear operational criteria to aid clinicians in diagnosing mental disorders (see box 1) and introduced the term major depressive disorder.

Since then major depressive disorder has received more research attention than any other diagnosis in psychiatry but has created many problems. The criteria, which have not changed since 1980, capture too heterogeneous a population for research studies and are so loose that, in everyday clinical practice, ordinary sadness can be easily confused wit clinical depression.<sup>5</sup>

#### Unhelpful classifications of mental disorders

Under DSM-III the term major depressiv disorder combined what had formerly bee described as "melancholia"-characterised b severe, disabling, and sometimes life threater ing depression, often coming out of the blu and characterised by marked diurnal variation suicidal thoughts, and somatic symptoms-wit "reactive depression." Reactive depression cor trasted in almost every way with melancholia with onset closely linked to a definable lif event and with symptoms that were milder and typically including sadness, loss of interest and feelings of guilt and unworthiness. Somati changes, including difficulty sleeping and los of appetite, were less profound and enduring in reactive depression than in melancholia. Those

## **DIAGNOSES IN OUR SERVICE**



#### PEOPLE WITH HIV REFERRED TO MENTAL HEALTH Principal Psychiatric Diagnosis (%)

Diagnosis	1990	1995	1999	2005
	(n=123)	(n=306)	(n=360)	(n=406)
Depression	21(17)	59(19)	98(27)	162(40)
Anxiety Disorder	6(3)	35(11)	48(13)	50(12)
Adjustment Disorder	33(27)	25(8)	44(12)	53(13)
Sexual Dysfunction	1(1)	5(2)	46(13)	56(14)
Substance misuse	21(17)	22(7)	32(9)	20(5)
Organic (acute)	5(4)	5(2)	14(4)	4(1)
Organic (chronic)	11(9)	18(6)	6(2)	9(2)
Mania	4(3)	7(2)	0(0)	6(1)
Schizophrenia	1(1)	2(1)	4(1)	1(0)
Others	-	-	-	31(8)

# WHAT INTERVENTIONS WORK?

Psychological therapies - CBT and related therapies - Long term therapies - Group therapies Physical method - Medication - ECT and other

NICE GUIDELINES FOR THE TREATMENT OF DEPRESSION IN PEOPLE WITH PHYSICAL DISORDERS

#### The stepped-care model

This model provides a framework for organising the provision of services, and helps patients, carers and practitioners to identify and access the most effective interventions. The least intrusive, most effective intervention is provided first. If a person does not benefit from that intervention, or declines an intervention, they should be offered an appropriate intervention from the next step.

> Focus of the intervention

**STEP 4**: Severe and complex depression; risk to life; severe self-neglect (see page 6)

**STEP 3**: Persistent subthreshold depressive symptoms or mild to moderate depression with inadequate response to initial interventions; moderate and severe depression (see page 6)

**STEP 2**: Persistent subthreshold depressive symptoms; mild to moderate depression (see page 5)

**STEP 1**: All known and suspected presentations of depression (see page 4)

Nature of the intervention

> Medication, high-intensity psychological interventions, electroconvulsive therapy, crisis service, combined treatments, multiprofessional and inpatient care


Medication, high-intensity psychological interventions, combined treatments, collaborative care and referral for further assessment and interventions

Low-intensity psychological and psychosocial interventions, medication and referral for further assessment and interventions

Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions

#### Step 1

#### **Identifying depression**



Subthreshold depressive symptoms: Fewer than 5 symptoms.

**Mild depression**: Few, if any, symptoms in excess of the 5 required to make the diagnosis, and symptoms result in only minor functional impairment.

Moderate depression: Symptoms or functional impairment are between 'mild' and 'severe'.

**Severe depression**: Most symptoms, and the symptoms markedly interfere with functioning. Can occur with or without psychotic symptoms.

<sup>1</sup> Taken from DSM-IV (see www.nice.org.uk/CG91niceguideline for further details).

#### Step 2

#### Sleep hygiene

- Offer advice on sleep hygiene, including:
  - establishing regular sleep and wake times
  - avoiding excess eating, smoking or drinking alcohol before sleep
  - creating a proper environment for sleep
  - taking regular physical exercise if possible.

#### Active monitoring

- For patients who may recover with no formal intervention, have mild depression and do not want an intervention, or have subthreshold depressive symptoms and request an intervention:
  - discuss the presenting problem(s) and any concerns
  - provide information about depression
  - arrange a further assessment, normally within 2 weeks
  - make contact if the patient does not attend appointments.

#### Low-intensity psychosocial interventions

- Consider offering one or more of the following to patients with persistent subthreshold depressive symptoms or mild to moderate depression, and to patients with subthreshold depressive symptoms that complicate the care of their chronic physical health problem:
  - a physical activity programme (modified for the particular physical health problem)
  - a peer support programme in a group of patients with a shared physical health problem
  - individual guided self-help based on cognitive behavioural therapy (CBT) principles
  - computerised CBT (CCBT)<sup>2</sup>. KPI
- For details of delivery of interventions, see section 1.4.2 of the NICE guideline (www.nice.org.uk/CG91niceguideline).

#### **Drug treatment**

- Do not use antidepressants routinely to treat subthreshold depressive symptoms or mild depression, but consider them for patients with:
  - a past history of moderate or severe depression or
  - mild depression that complicates the care of the physical health problem or
  - initial presentation of subthreshold depressive symptoms present for at least 2 years or
  - subthreshold depressive symptoms or mild depression persisting after other interventions. KPI
- Do not prescribe or advise use of St John's wort. Explain about the different potencies of the preparations available and potential serious interactions with other drugs.

#### Step 3

rget population	Treatment options
Patients with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention	<ul> <li>An antidepressant (see pages 8–9) or</li> <li>A high-intensity psychological intervention (group CBT, individual CBT or behavioural couples therapy)<sup>3</sup>.</li> </ul>
Patients who present initially with moderate depression	<ul> <li>A high-intensity psychological intervention (group CBT, individual CBT or behavioural couples therapy)<sup>3</sup>. KPI</li> </ul>
Patients who present initially with severe depression	<ul> <li>Consider offering both individual CBT<sup>3</sup> and an antidepressant (see pages 8–9).</li> </ul>

- When choosing an intervention, take into account:
  - duration of episode and trajectory of symptoms
  - previous course of depression and response to treatment
  - likelihood of adherence to treatment and potential adverse effects
  - course and treatment of the chronic physical health problem
  - patient's treatment preference.

#### Patients with moderate or severe depression who have not responded to initial interventions

- Consider collaborative care for patients whose depression has not responded to initial high-intensity psychological interventions, pharmacological treatment or a combination of psychological and pharmacological interventions. *KPI*
- Collaborative care should include case management supervised by a senior mental health professional, close collaboration between physical health services and specialist mental health services, interventions as described above, and long-term coordination of care and follow-up.
- For details of treatment options, see www.nice.org.uk/CG90quickrefguide

#### Step 4

- Interventions may include medication, high-intensity psychological interventions, electroconvulsive therapy and other physical treatments, combined treatments, crisis resolution and home treatment teams, and inpatient care (for further details, see www.nice.org.uk/CG90niceguideline).
- If treatment is provided by specialist mental health services for patients with complex and severe depression, there should be close collaboration with services treating the physical health problem.

# ANTIDEPRESSANTS and ARV

There are potential interactions, but in most cases they lead to increased levels of antidepressant (SSRIs & venlafaxine), rather than lowering of ARV levels

PI are the most likely to increase anticlepressant levels

Mirtazapine has no known interactions

St John's wort can reduce levels of PI & nevirapine

# Searching for possible interactions <a href="http://www.hiv-druginteractions.org">http://www.hiv-druginteractions.org</a>

UNIVERSITY OF

	www.hiv-druginteractions.org																				
	月月				lep													eta	or		
CI	Charts reviewed February 2014. Full information available at www.hiv-druginteractions.org and www.hiv-druginteractionslite.org																				
Γ	Τ		ATV/r	DRV/r	FPV/r	IDV/r	LPV/r	SQV/r	EFV	ETV	NVP	RPV	MVC	DTG	EVG/c	RAL	ABC	FTC	3TC	TDF	ZDV
Γ		Citalopram	↑ <sup>a</sup>	1	î	î	↑ ª	↑ <sup>a</sup>	Ļ	Ļ	Ļ	$\leftrightarrow$	$\leftrightarrow$	↔	î	$\leftrightarrow$	$\leftrightarrow$	↔	$\leftrightarrow$		↔
		Escitalopram	↑ <b>°</b>	Ť	î	Ť	1ª	† ª	Ļ	1	Ļ	$\leftrightarrow$	↔		î	$\leftrightarrow$	↔	$\leftrightarrow$	$\leftrightarrow$	$\leftrightarrow$	↔
ā		Fluvoxamine	î	Ť	Ť	t	t	1	↔	↔		$\leftrightarrow$			î	<b>↔</b>	$\leftrightarrow$	<->	$\leftrightarrow$	$\leftrightarrow$	↔
<i>a</i>	5	Fluoxetine	î	î	î	1	Ť	1	↔	↔	↔	↔	4	↔	î	$\leftrightarrow$	$\leftrightarrow$	$\leftrightarrow$	↔	↔	↔
		Paroxetine	117	<b>↓39%</b>	150%	†↓?	112	112	↔	↔	↔	$\leftrightarrow$	+	+	†↓ ?	$\leftrightarrow$	$\leftrightarrow$	↔	++		↔
		Sertraline	Ļ	<b>↓49%</b>	Ļ	Ļ	Ļ	Ļ	<b>↓39%</b>	Ļ	Ļ	$\leftrightarrow$		$\leftrightarrow$	î	•••		↔	↔		<ul> <li>↔</li> </ul>
SNRI		Duloxetine	†↓	†↓	†↓	ţ1	ţţ	ţ†	↔	↔	$\leftrightarrow$			$\leftrightarrow$	î	$\leftrightarrow$	$\leftrightarrow$	↔	$\leftrightarrow$	$\leftrightarrow$	< <b>↔</b>
S	5	Venlafaxine	Ť	î	î	Ť	î	Ť	Ļ	Ļ	Ļ	↔	↓	↔	Ť	↔	↔	$\leftrightarrow$	$\leftrightarrow$	↔	<del>()</del>
		Amitriptyline	1	Ť	î	Ť	1	1°	$\leftrightarrow$	$\leftrightarrow$	↔	< <b>↔</b>	↔	↔	Ť	+>	$\leftrightarrow$	$\leftrightarrow$	↔	$\leftrightarrow$	< <b>↔</b>
	ŀ	Clomipramine	Ť	1	Ť	t	1	1 <sup>6</sup>	Ļ	Ļ	Ļ	↔	+	↔	î	↔	↔	↔		$\leftrightarrow$	↔
	-	Desipramine	î	î	î	t	↑5%	1		< <b>→</b>	++	++			Î	↔		++	↔	↔	↔
TC		Doxepin	1	Î	Î	Ť	î	ť	++	< <b>↔</b>	↔	↔			Î		↔ 	↔ 	$\leftrightarrow$	↔ 	↔
		Imipramine	† ª	Ť	Î	1	t*	†*	ţ	Ļ	Ļ	<->	< <b>↔</b>		Î	$\leftrightarrow$	<->	< <b>↔</b>	<->	<->	< <b>↔</b>
	+	Nortriptyline	î ª	Ť	Ť	Ť	↑ ª	1 <sup>ab</sup>	↔ 	$\leftrightarrow$	↔	↔	++	↔ 	Ť	↔ 	↔ 	↔	↔	↔	↔ 
		Trimipramine	1 I	t	Ť	1	1	1	↔	<+>	↔	↔		<del>(-)</del>	Ť	↔	↔	↔	↔	↔	↔
ToC.A	-	Maprotiline	Î	Ť	1 t	Ť	1	1	↔		↔	↔ 	↔	↔	↑ ↑	↔ ↔		↔			↔
Tol		Mianserine	1 T	↑ ↑	Ť	Ť Ť	1 t	1 1	+	+	1	↔ ;	+	4	Ť	↔	↔				↔
		Mirtazapine	1	1			157%	1	↓ 155%	↓ ↔	+	↔	↔	↔	1?	↔	++	↔	↔	↔	↔
	I.	Bupropion	↓ ↓32%	+	+	+	157%	+	100%	↔ ↔	+	↔ ↔	↔	↔	+ 1 (→	↔	(-)				<->
Othore	0	Lamotrigine	13270	+	÷ †	t T	10070	1	1	11	1	Ĥ	ſ	ſ	1	<+→	↔	(-)	++	↔	↔
đ	18.	Nefazodone	U	U	IJ	U	IJ	U	U.	4	4 H	ų	-U	11°	IJ	↔		↔	↔		<->
	t,	St John's wort		•				+b	-				↔	↔	+	++	44 44		↔		↔
		Trazodone	Ť	T	Г	I	L. I.	1. A.	+	1	+										

#### Colour Legend

No clinically significant interaction expected

These drugs should not be coadministered.

Potential interaction which may require a dosage adjustment or close monitoring.

Potential interaction predicted to be of weak intensity (<2 fold ↑AUC or <50% ↓AUC). No a priori dosage adjustment is recommended.

## Lessening the burden

Patient Preference and Adherence

8 Open Access Full Text Article

Dovepress open access to scientific and medical research

ORIGINAL RESEARCH

Factors that lessen the burden of treatment in complex patients with chronic conditions: a qualitative study

Jennifer L Ridgeway<sup>1,2</sup> Jason S Egginton<sup>1,2</sup> Kristina Tiedje<sup>3</sup> Mark Linzer<sup>4,5</sup> Deborah Boehm<sup>4</sup> Sara Poplau<sup>6</sup> Djenane Ramalho de Oliveira<sup>7</sup> Laura Odell<sup>8</sup> Victor M Montori<sup>2,9</sup> David T Eton<sup>1,2</sup>

<sup>1</sup>The Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, <sup>2</sup>Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; <sup>3</sup>Department of Anthropology, Université Lumière Lyon 2, Lyon, France; <sup>4</sup>Division of General Internal Medicine, Hennepin County Medical Center, <sup>5</sup>University of Minnesota Medical School, <sup>6</sup>Minneapolis Medical Research Foundation, Minneapolis, MN, USA; <sup>7</sup>Department of Social Pharmacy, Universidade Federal **Purpose:** Patients with multiple chronic conditions (multimorbidity) often require ongoing treatment and complex self-care. This workload and its impact on patient functioning and wellbeing are, together, known as treatment burden. This study reports on factors that patients with multimorbidity draw on to lessen perceptions of treatment burden.

**Patients and methods:** Interviews (n=50) and focus groups (n=4 groups, five to eight participants per group) were conducted with patients receiving care in a large academic medical center or an urban safety-net hospital. Interview data were analyzed using qualitative framework analysis methods, and themes and subthemes were used to identify factors that mitigate burden. Focus groups were held to confirm these findings and clarify any new issues. This study was part of a larger program to develop a patient-reported measure of treatment burden.

**Results:** Five major themes emerged from the interview data. These included: 1) problemfocused strategies, like routinizing self-care, enlisting support of others, planning for the future, and using technology; 2) emotion-focused coping strategies, like maintaining a positive attitude, focusing on other life priorities, and spirituality/faith; 3) questioning the notion of treatment burden as a function of adapting to self-care and comparing oneself to others; 4) social support (informational, tangible, and emotional assistance); and 5) positive aspects of health care, like coordination of care and beneficial relationships with providers. Additional subthemes arising from focus groups included preserving autonomy/independence and being proactive with providers.

**Conclusion:** Patients attempt to lessen the experience of treatment burden using a variety of personal, social, and health care resources. Assessing these factors in tandem with patient perceptions of treatment burden can provide a more complete picture of how patients fit complex self-care into their daily lives.

### Resources for easing treatment burden diagram

Table 2 Resources for easing treatment burden by data collection method Themes and subthemes Interviews Focus groups Theme I Problem-focused strategies x × Routinizing self-care X х Enlisting support from others x x Planning for the future x х Using technology × × Preserving autonomy/independence x Being proactive with providers x Theme 2 Emotion-focused coping X x Maintaining positive attitude × × Focusing on other life priorities x x Spirituality and faith x x Theme 3 Questioning the notion of burden X X Adaptation/normalizing self-care × х Social comparison with others × x Theme 4 Receiving support from others x × Informational X x Instrumental x x Emotional/companionship × × Theme 5 Positive aspects of health care × x Systemic aspects × x Individual-provider aspects × x

Dovepress

## **1.PROBLEM FOCUSED STRATEGIES**

- Routinizing self-care
   Enlisting support from others
   Planning for the future
- Using technology
- Preserving autonomy
- Being proactive with providers

## **2.EMOTION FOCUSED COPING**

- Maintaining positive attitude
- Focusing on other life priorities
- Spirituality and faith

# 3. QUESTIONING THE NOTION OF BURDEN

Adaptation/normalizing self-care
 Social comparison with others

## 4. RECEIVING SUPPORT FROM OTHERS

- Information
- Instrumental
- Emotional/companionship

## 5. POSITIVE ASPECTS OF HEALTH CARE

Systemic aspects

Person-provider aspects

Over 225,000 in print. A proven program from leading scientists. y Includes a CD of guided meditations **byjoti Kabat-Zinn** 



### Mindful Way through Depression

Freeing Yourself from chronic Unhappiness



Mark Williams, John Teasdale, Zindel Segal, and Jon Kabat-Zinn

## REFERENCES

- Sherr, Clucas, Harding, Sibley & Catalan (2011) HIV and depression: a systematic review of interventions. Psychology, Health and Medicine, 1-35.
- NICE (2009) Depression in adults with a chronic physical health problem. Guidelines 90 & 91.
- Ridgeway, Eggington, Tiedje, Linzer, Boehm, Poplau, Oliveira, Odell, Montori & Eton (2014) Factors that lessen the burden of treatment in complex patients with chronic conditions. Patient Preference and Adherence, 8, 339-351.
- Dowrick & Frances (2013) Medicalising and medicating unhappiness. British Medical Journal, 347, 20-23.
- Standards for Psychological Support for adults living with HIV (2011) Published by BHIVA, BPS & MedFASH, London